COUNTRY
|
LATEST DELIVERY
|
DELIVERY DATE
|
VACCINE TYPE
|
POPULATION
|
TOTAL DELIVERED
|
---|---|---|---|---|---|
Algeria
|
3.6 million
|
December 24
|
J&J
|
44 million
|
6.0 million
|
Angola
|
801,000
|
December 25
|
Pfizer/BioNTech
|
33 million
|
14.8 million
|
Benin
|
336,000
|
November 4
|
J&J
|
12 million
|
1.1 million
|
Botswana
|
300,000
|
October 1
|
AstraZeneca/Oxford
|
2.5 million
|
560,460
|
Burkina Faso
|
504,000
|
December 22
|
J&J
|
21 million
|
1.1 million
|
Cameroon
|
336,000
|
November 5
|
J&J
|
27 million
|
1.0 million
|
Cape Verde
|
200,000
|
December 7
|
Pfizer/BioNTech
|
556,000
|
324,000
|
Central African Republic
|
168,300
|
November 19
|
J&J
|
4.8 million
|
806,700
|
Chad
|
117,000
|
October 5
|
Pfizer/BioNTech
|
16 million
|
217,620
|
Comoros Islands
|
12,000
|
April 12
|
AstraZeneca/Oxford
|
870,000
|
12,000
|
Congo
|
168,000
|
November 15
|
J&J
|
5.5 million
|
470,400
|
Democratic Republic of Congo
|
349,830
|
October 21
|
Pfizer/BioNTech
|
90 million
|
2.6 million
|
Djibouti
|
151,200
|
July 17
|
J&J
|
988,000
|
175,200
|
Egypt
|
2.2 million
|
February 20
|
Pfizer/BioNTech
|
102 million
|
29.0 million
|
Eswatini
|
100,620
|
October 6
|
Pfizer/BioNTech
|
1.1 million
|
429,420
|
Ethiopia
|
13.1 million
|
February 2
|
J&J
|
115 million
|
27.5 million
|
Gabon
|
101,790
|
November 1
|
Pfizer/BioNTech
|
2.2 million
|
370,410
|
Gambia
|
100,620
|
March 3
|
Pfizer/BioNTech
|
2.4 million
|
477,420
|
Ghana
|
1.7 million
|
December 24
|
Pfizer/BioNTech
|
31 million
|
16.3 million
|
Guinea
|
168,000
|
November 14
|
J&J
|
13 million
|
1.7 million
|
Guinea-Bissau
|
28,800
|
August 18
|
AstraZeneca/Oxford
|
2.0 million
|
360,000
|
Iran
|
700,000
|
January 14
|
AstraZeneca/Oxford
|
84 million
|
5.7 million
|
Iraq
|
500,000
|
August 14
|
Pfizer/BioNTech
|
40 million
|
836,000
|
Ivory Coast
|
816,660
|
January 3
|
Pfizer/BioNTech
|
26 million
|
8.6 million
|
Jordan
|
146,400
|
June 3
|
AstraZeneca/Oxford
|
10 million
|
436,800
|
Kenya
|
1.9 million
|
February 28
|
Pfizer/BioNTech
|
54 million
|
18.6 million
|
Lebanon
|
613,340
|
December 22
|
N/A
|
6.8 million
|
982,940
|
Lesotho
|
169,070
|
November 19
|
J&J
|
2.1 million
|
644,090
|
Liberia
|
168,000
|
November 27
|
J&J
|
5.1 million
|
830,400
|
Libya
|
1.2 million
|
December 20
|
Pfizer/BioNTech
|
6.9 million
|
1.9 million
|
Madagascar
|
240,000
|
February 17
|
J&J
|
28 million
|
1.9 million
|
Malawi
|
277,080
|
February 26
|
AstraZeneca/Oxford
|
19 million
|
2.0 million
|
Mali
|
50,400
|
January 7
|
AstraZeneca/Oxford
|
20 million
|
1.7 million
|
Mauritania
|
201,600
|
February 7
|
AstraZeneca/Oxford
|
4.6 million
|
2.2 million
|
Mauritius
|
203,580
|
January 12
|
Pfizer/BioNTech
|
1.3 million
|
387,270
|
Morocco
|
1.5 million
|
January 29
|
Pfizer/BioNTech
|
37 million
|
2.7 million
|
Mozambique
|
1.2 million
|
February 11
|
AstraZeneca/Oxford
|
31 million
|
8.4 million
|
Namibia
|
19,890
|
February 18
|
Pfizer/BioNTech
|
2.5 million
|
512,690
|
Niger
|
398,000
|
February 4
|
Pfizer/BioNTech
|
24 million
|
1.6 million
|
Nigeria
|
2.0 million
|
February 7
|
J&J
|
206 million
|
17.2 million
|
Palestinian Territories
|
203,580
|
January 31
|
Pfizer/BioNTech
|
4.7 million
|
1.3 million
|
Rwanda
|
1.1 million
|
January 15
|
N/A
|
13 million
|
3.9 million
|
Sao Tome and Principe
|
24,000
|
March 3
|
AstraZeneca/Oxford
|
219,000
|
24,000
|
Senegal
|
302,400
|
February 10
|
J&J
|
17 million
|
3.2 million
|
Seychelles
|
39,780
|
December 17
|
Pfizer/BioNTech
|
98,460
|
74,880
|
Sierra Leone
|
168,000
|
November 23
|
J&J
|
8.0 million
|
785,310
|
Somalia
|
250,380
|
March 3
|
Pfizer/BioNTech
|
16 million
|
1.4 million
|
South Africa
|
5.6 million
|
July 31
|
Pfizer/BioNTech
|
59 million
|
5.6 million
|
South Sudan
|
336,000
|
December 21
|
J&J
|
11 million
|
908,450
|
Sudan
|
604,800
|
February 16
|
J&J
|
44 million
|
3.9 million
|
Syria
|
4.0 million
|
January 26
|
J&J
|
17 million
|
5.7 million
|
Tanzania
|
1.6 million
|
January 19
|
Pfizer/BioNTech
|
60 million
|
4.7 million
|
Togo
|
633,600
|
November 25
|
J&J
|
8.3 million
|
3.0 million
|
Tunisia
|
310,050
|
January 28
|
Pfizer/BioNTech
|
12 million
|
4.4 million
|
Uganda
|
433,300
|
February 16
|
Moderna
|
46 million
|
11.7 million
|
Yemen
|
100,800
|
February 24
|
AstraZeneca/Oxford
|
30 million
|
2.2 million
|
Zambia
|
907,200
|
January 28
|
N/A
|
18 million
|
4.0 million
|
Zimbabwe
|
2.6 million
|
January 19
|
N/A
|
15 million
|
3.5 million
|
You are here
Vaccines delivered under COVAX sharing scheme for poorer countries --data
Primary tabs
Fri, 2022-03-04 11:12 — mike kraft
Factbox: Vaccines delivered under COVAX sharing scheme for poorer countries The COVAX facility, backed by the World Health Organization (WHO) and the Global Alliance for Vaccines and Immunization (GAVI), has delivered 1.34 billion COVID-19 vaccine doses to 144 countries, GAVI data shows. Reuters
March 4 (Reuters) - The COVAX facility, backed by the World Health Organization (WHO) and the Global Alliance for Vaccines and Immunization (GAVI), has delivered 1.34 billion COVID-19 vaccine doses to 144 countries, GAVI data shows.
In December COVAX set a target of achieving 70% COVID-19 immunization coverage by mid-2022.
The following tables list countries that have received vaccines under the scheme, sorted alphabetically:
AFRICA & MIDDLE EAST
EUROPE
COUNTRY
|
LATEST DELIVERY
|
DELIVERY DATE
|
VACCINE TYPE
|
POPULATION
|
TOTAL DELIVERED
|
---|---|---|---|---|---|
Albania
|
40,800
|
June 2
|
AstraZeneca/Oxford
|
2.8 million
|
120,000
|
Armenia
|
187,200
|
September 5
|
AstraZeneca/Oxford
|
3.0 million
|
261,200
|
Azerbaijan
|
84,000
|
April 4
|
AstraZeneca/Oxford
|
10 million
|
84,000
|
Bosnia
|
32,760
|
May 10
|
Pfizer/BioNTech
|
3.3 million
|
82,560
|
Georgia
|
43,200
|
March 13
|
AstraZeneca/Oxford
|
3.7 million
|
43,200
|
Kosovo
|
515,970
|
February 10
|
Pfizer/BioNTech
|
1.8 million
|
1.2 million
|
Moldova
|
100,620
|
January 27
|
Pfizer/BioNTech
|
2.6 million
|
744,620
|
Montenegro
|
24,000
|
March 28
|
AstraZeneca/Oxford
|
622,000
|
24,000
|
North Macedonia
|
250,380
|
February 7
|
Pfizer/BioNTech
|
2.1 million
|
312,780
|
Serbia
|
115,200
|
August 25
|
AstraZeneca/Oxford
|
6.9 million
|
292,800
|
Ukraine
|
1.0 million
|
January 19
|
Pfizer/BioNTech
|
44 million
|
8.8 million
|
ASIA & PACIFIC
COUNTRY
|
LATEST DELIVERY
|
DELIVERY DATE
|
VACCINE TYPE
|
POPULATION
|
TOTAL DELIVERED
|
---|---|---|---|---|---|
Afghanistan
|
2.0 million
|
February 2
|
J&J
|
39 million
|
9.0 million
|
Bangladesh
|
342,400
|
February 2
|
Pfizer/BioNTech
|
165 million
|
34.8 million
|
Brunei
|
24,000
|
April 2
|
AstraZeneca/Oxford
|
437,000
|
24,000
|
Cambodia
|
300,000
|
December 19
|
AstraZeneca/Oxford
|
17 million
|
2.9 million
|
East Timor
|
100,620
|
February 12
|
Pfizer/BioNTech
|
1.3 million
|
494,040
|
Fiji
|
50,400
|
November 18
|
Moderna
|
896,000
|
302,480
|
Indonesia
|
2.6 million
|
January 28
|
AstraZeneca/Oxford
|
274 million
|
48.8 million
|
Kiribati
|
56,000
|
August 21
|
AstraZeneca/Oxford
|
119,000
|
104,000
|
Kyrgyzstan
|
149,760
|
February 1
|
Pfizer/BioNTech
|
6.6 million
|
800,300
|
Laos
|
1.7 million
|
January 26
|
Pfizer/BioNTech
|
7.3 million
|
7.6 million
|
Malaysia
|
559,200
|
September 17
|
AstraZeneca/Oxford
|
32 million
|
1.4 million
|
Maldives
|
210,600
|
January 28
|
Pfizer/BioNTech
|
541,000
|
664,540
|
Mongolia
|
899,730
|
October 6
|
Pfizer/BioNTech
|
3.3 million
|
1.3 million
|
Nauru
|
7,200
|
April 2
|
AstraZeneca/Oxford
|
10,830
|
7,200
|
Nepal
|
800,000
|
February 7
|
AstraZeneca/Oxford
|
29 million
|
14.2 million
|
Pakistan
|
1.5 million
|
December 28
|
Moderna
|
221 million
|
39.1 million
|
Papua New Guinea
|
302,400
|
August 6
|
J&J
|
8.9 million
|
580,400
|
Philippines
|
769,860
|
March 3
|
Pfizer/BioNTech
|
110 million
|
52.6 million
|
Samoa
|
112,000
|
August 23
|
AstraZeneca/Oxford
|
198,410
|
136,000
|
Solomon Islands
|
100,620
|
November 16
|
Pfizer/BioNTech
|
687,000
|
209,420
|
Sri Lanka
|
820,000
|
December 20
|
Pfizer/BioNTech
|
22 million
|
5.0 million
|
Tajikistan
|
501,200
|
February 21
|
AstraZeneca/Oxford
|
9.5 million
|
5.4 million
|
Tonga
|
7,000
|
February 15
|
N/A
|
106,000
|
67,800
|
Tuvalu
|
4,800
|
April 8
|
AstraZeneca/Oxford
|
11,800
|
4,800
|
Uzbekistan
|
2.8 million
|
February 17
|
Moderna
|
34 million
|
12.7 million
|
Vanuatu
|
24,000
|
May 19
|
AstraZeneca/Oxford
|
307,000
|
24,000
|
Vietnam
|
6.3 million
|
January 25
|
Pfizer/BioNTech
|
97 million
|
38.7 million
|
AMERICAS
COUNTRY
|
LATEST DELIVERY
|
DELIVERY DATE
|
VACCINE TYPE
|
POPULATION
|
TOTAL DELIVERED
|
---|---|---|---|---|---|
Antigua and Barbuda
|
19,200
|
November 22
|
N/A
|
98,000
|
60,000
|
Argentina
|
960,400
|
October 12
|
AstraZeneca/Oxford
|
45 million
|
3.9 million
|
Bahamas
|
57,330
|
October 18
|
Pfizer/BioNTech
|
393,000
|
124,530
|
Barbados
|
14,040
|
December 16
|
Pfizer/BioNTech
|
287,000
|
114,840
|
Belize
|
58,500
|
October 26
|
Pfizer/BioNTech
|
398,000
|
159,300
|
Bermuda
|
9,600
|
April 6
|
AstraZeneca/Oxford
|
64,000
|
9,600
|
Bolivia
|
1.3 million
|
February 16
|
Pfizer/BioNTech
|
12 million
|
8.0 million
|
Brazil
|
2.0 million
|
September 20
|
Sinovac
|
213 million
|
11.9 million
|
Chile
|
331,000
|
May 20
|
AstraZeneca/Oxford
|
19 million
|
489,400
|
Colombia
|
117,000
|
March 1
|
Pfizer/BioNTech
|
51 million
|
16.6 million
|
Costa Rica
|
200,070
|
February 28
|
Pfizer/BioNTech
|
5.1 million
|
1.6 million
|
Dominica
|
30,240
|
February 4
|
Moderna
|
72,000
|
133,920
|
Dominican Republic
|
184,800
|
August 27
|
AstraZeneca/Oxford
|
11 million
|
463,200
|
Ecuador
|
1.5 million
|
February 15
|
Pfizer/BioNTech
|
18 million
|
3.8 million
|
El Salvador
|
188,370
|
August 27
|
Pfizer/BioNTech
|
6.5 million
|
3.6 million
|
Grenada
|
69,030
|
December 16
|
Pfizer/BioNTech
|
113,000
|
114,630
|
Guatemala
|
680,940
|
January 27
|
Pfizer/BioNTech
|
17 million
|
5.0 million
|
Guyana
|
28,800
|
January 14
|
J&J
|
787,000
|
291,540
|
Haiti
|
151,200
|
February 14
|
Moderna
|
11 million
|
1.1 million
|
Honduras
|
250,040
|
October 28
|
Moderna
|
9.9 million
|
4.8 million
|
Jamaica
|
100,000
|
February 21
|
AstraZeneca/Oxford
|
3.0 million
|
1.7 million
|
Mexico
|
4.0 million
|
March 4
|
AstraZeneca/Oxford
|
129 million
|
21.3 million
|
Nicaragua
|
993,600
|
January 24
|
J&J
|
6.6 million
|
4.7 million
|
Panama
|
74,400
|
September 15
|
AstraZeneca/Oxford
|
4.3 million
|
148,800
|
Paraguay
|
466,830
|
January 24
|
Pfizer/BioNTech
|
7.1 million
|
1.7 million
|
Peru
|
1.2 million
|
November 10
|
Sinopharm
|
33 million
|
3.6 million
|
Saint Kitts and Nevis
|
21,600
|
April 7
|
AstraZeneca/Oxford
|
53,000
|
21,600
|
Saint Lucia
|
7,200
|
December 28
|
J&J
|
184,000
|
197,430
|
Saint Vincent and the Grenadines
|
70,200
|
December 14
|
Pfizer/BioNTech
|
111,000
|
115,800
|
Suriname
|
64,800
|
December 14
|
AstraZeneca/Oxford
|
587,000
|
144,000
|
Trinidad and Tobago
|
84,000
|
November 27
|
Sinopharm
|
1.4 million
|
185,200
|
Uruguay
|
50,400
|
September 1
|
AstraZeneca/Oxford
|
3.5 million
|
148,800
|
Venezuela
|
3.1 million
|
January 17
|
Sinopharm
|
28 million
|
12.1 million
|
Sources: WHO, UNICEF, GAVI, releases from local authorities
###
Country / Region Tags:
General Topic Tags:
Problem, Solution, SitRep, or ?:
Groups this Group Post belongs to:
Recent Comments